Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02438215 · ClinicalTrials.gov registry record · Phase 1
Study of IRX4204 for Treatment of Early Parkinson's Disease
A Phase 1 study, sponsored by Io Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02438215 is a Phase 1 study that has completed, run by Io Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT02438215, a Phase 1 study, has completed, sponsored by Io Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a single site, open-label study designed to examine dopamine transporter density using \[123I\]β-CIT SPECT imaging before and following treatment with IRX4204 for a 30-day period in early Parkinson's disease patients. In addition, clinical evaluations will be performed to evaluate the effect of IRX4204 treatment on the motor and cognitive symptoms of PD.
Interventions
- DRUG IRX4204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02438215
The ClinicalTrials.gov registry entry for NCT02438215 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Io Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IRX4204 is the first listed.
NCT02438215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02438215 about?
NCT02438215 is a clinical study titled "Study of IRX4204 for Treatment of Early Parkinson's Disease". This is a single site, open-label study designed to examine dopamine transporter density using \[123I\]β-CIT SPECT imaging before and following treatment with IRX4204 for a 30-day period in early Parkinson's disease patients. In addition, clinical evaluations will be performed to evaluate the effect...
What is the current status of trial NCT02438215?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-08. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02438215?
The interventions under investigation include: IRX4204 (DRUG).
Who is sponsoring clinical trial NCT02438215?
This trial is sponsored by Io Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.